About Neumora
Neumora is a company based in Watertown (United States) founded in 2020 by Robert Nelsen, Kristina Burow, Carol Suh, Paul Berns, and Mike Poole. Neumora has raised $612 million across 2 funding rounds from investors including Amgen, ARE and Citadel. The company has 110 employees. Neumora offers products and services including Precision Toolbox and Drug Pipeline Programs. Neumora operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Watertown, United States
- Employees 110
- Founders Robert Nelsen, Kristina Burow, Carol Suh, Paul Berns, Mike Poole
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website neumoratx.com
- Social LinkedIn X
- Legal Name Neumora Therapeutics, Inc.
- Net Profit-$236.93 M (USD)2.81as on Dec 31, 2025
- EBITDA-$235.95 M (USD)10.23as on Dec 31, 2025
- Total Equity Funding$612M (USD)
in 2 rounds
- Latest Funding Round$112M (USD), Series B
Oct 2022
- InvestorsAmgen
& 16 more
- Employee Count110
Products & Services of Neumora
Neumora offers a comprehensive portfolio of products and services, including Precision Toolbox and Drug Pipeline Programs.
Integrates tools for precision medicine in CNS diseases.
Pursues novel mechanisms for brain disease treatments.
Funding Insights of Neumora
Neumora has successfully raised a total of $612M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $112 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $612M
- Total Rounds 2
- Last Round Series B — $112M
- First Round $500M
(Oct 2021)
- Investors Count 17
All 2 funding rounds of Neumora with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2022 | $112M | Series B | – | Amgen, Arch Venture Partners | – |
| Oct 2021 | $500M | Series A | – | Arch Venture Partners |
17 investors in total: 17 institutional.
Investors in Neumora
Neumora has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, ARE and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Early stage life sciences sectors focused VC firm investing in the US | – | altitudelsv.com | Kirkland, United States | |
Venture capital is provided to biomedical technology startups. | – | cataliocapital.com | New York, United States | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Investment management services are offered by Newpath Partners. | – | newpath.partners | Boston, United States | |
Private equity fund focused on the biotechnology sector | – | logoscapital.com | San Francisco, United States | |
US focused venture capital firm | – | polarispartners.com | Boston, United States | |
Early-stage investments are provided in mental health and brain health sectors. | – | remind.vc | London, United Kingdom | |
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom |
Investor details for Neumora
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Neumora
63 people are tracked at Neumora (43 in leadership, 11 in board & advisors, 9 in team); the tracked headcount is 110.
| Name | Role | Group |
|---|---|---|
Robert Nelsen | Co-Founder | Leadership |
Kristina Burow | Co-Founder | Leadership |
Carol Suh | Co-Founder & CSO | Leadership |
Paul Berns | Co-Founder & CEO | Leadership |
Mike Poole | Co-Founder & Advisor | Leadership |
Hong Ji | Director, Analytical Development And Quality Control | Leadership |
Raj Manchanda | Chief Technical Operations Officer | Leadership |
Linda Peterson | Sr. Director, Total Rewards & HR Operations | Leadership |
Claire Scarbrough Joyce | Vp, Talent | Leadership |
James Douberley | Head Of Facilities | Leadership |
Fatima Zaidi | Head Of Clinical Supply Chain | Leadership |
Sarah Gilroy | Senior Director, Clinical Site Operations | Leadership |
Debbie Chan | Director, Quality Document Control & Training | Leadership |
Lauren Herl Martens | Vp, Biology | Leadership |
Karla Zeitz | Director, Toxicology | Leadership |
Palwasha Talib | Vp, Controller | Leadership |
Chelsea Toner | Associate Director Clinical Operations | Leadership |
Jason G. Duncan | Chief Legal And Administrative Officer | Leadership |
Amanda Williams | Senior Director Medical Affairs | Leadership |
Sunita Malhotra | Senior Director, Alliance Management | Leadership |
43 more people are available in the full profile.
Complete people profiles for Neumora
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Neumora
Neumora is a publicly listed company on the NASDAQ with ticker symbol NMRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Sep 2023
- Listed onNASDAQ: NMRA
- Listed entityNeumora Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS6409791000
- Share price$0.48 (+2.46% on the day) · 2026-10-08
- Market capitalisation$90.2M
- EPS (diluted, trailing year)$-1.23
- Volume (last session)1,811,295
Financials of Neumora
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$236.9M | -$235.9M |
| 2024 | – | -$243.8M | -$262.8M |
| 2023 | – | -$235.9M | -$187.5M |
| 2022 | – | -$130.9M | -$120.2M |
| 2021 | – | -$237.3M | -$78.8M |
Detailed financial statements for Neumora
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Neumora
4 dated milestones of Neumora across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Neumora is founded.
- Funding First funding round of $500.0M.
- Funding Latest funding round, Series B, of $112.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Neumora
Neumora operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| pacira.com | 2006 | Parsippany Troy Hills, United States | $85M | 712 | Injectable non-opioid products for post-surgical pain control are developed. |
Detailed competitors of Neumora
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Neumora
The website of Neumora (neumoratx.com) receives about 10K visits a month and ranks #2,571,645 among all websites worldwide, #3,526 in Biotechnology and Pharmaceuticals.
- Monthly visits10K
▲ 16.2% vs previous month
- Unique visitors3.7K
per month
- Global rank#2,571,645
among all websites
- Category rank#3,526
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.7
- Average visit31 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Neumora. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bioworld.com | bioworld.com | 100% | – | #311,180 | – |
Latest news on Neumora
Complete news archive for Neumora
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Neumora
10 companies that operate in the same segment as Neumora (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neumora
Neumora was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Neumora is headquartered in Watertown, United States.
Paul Berns is the current CEO of Neumora. They have also founded this company.
Neumora is a funded company, having raised a total of $612M across 2 funding rounds to date. The company's 1st funding round was a Series A of $500M, raised on Oct 2021.
Neumora has 110 employees.
Neumora was founded in 2020 and is headquartered in Watertown, United States. Precision medicines targeting neuropsychiatric and neurodegenerative disorders are developed through a data-driven neuroscience platform. Technologies such as Data Biopsy Signatures and Precision Phenotypes are utilized to enable targeted therapies for brain diseases. The pipeline encompasses NMRA-140 for depressive disorders, NMRA-511 for anxiety and sleep issues, and NMRA-094 for neurodegenerative conditions.
Neumora's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Neumora offers Precision Toolbox and Drug Pipeline Programs.
Yes, Neumora is publicly traded on NASDAQ under the ticker symbol NMRA.
Neumora has 17 investors. Key investors include Amgen, ARE, Citadel, Mubadala, and Arch Venture Partners.
Neumora operates through Neumora Therapeutics, Inc.